Sun Pharma Agrees to Buy Struggling Ranbaxy from Daiichi Sankyo in US$4 B Deal
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 5 (Table of Contents)
Published: 9 May-2014
DOI: 10.3833/pdr.v2014.i5.2024 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Daiichi Sankyo has decided to sell its majority stake in Ranbaxy Laboratories to India’s Sun Pharmaceutical Industries as part of an all-stock deal that values the company at approximately US$4 B, including debt, and which will create the world’s fifth-largest speciality generics manufacturer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS